These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 11742881

  • 1. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice.
    Davis HR, Compton DS, Hoos L, Tetzloff G.
    Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):2032-8. PubMed ID: 11742881
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice.
    Davis HR, Hoos LM, Tetzloff G, Maguire M, Zhu LJ, Graziano MP, Altmann SW.
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):841-9. PubMed ID: 17218600
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Supplementation with curcumin inhibits intestinal cholesterol absorption and prevents atherosclerosis in high-fat diet-fed apolipoprotein E knockout mice.
    Zou J, Zhang S, Li P, Zheng X, Feng D.
    Nutr Res; 2018 Aug; 56():32-40. PubMed ID: 30055772
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of Antiatherogenic Properties of Ezetimibe Using 3H-Labeled Low-Density-Lipoprotein Cholesterol and 99mTc-cAbVCAM1-5 SPECT in ApoE-/- Mice Fed the Paigen Diet.
    Dumas LS, Briand F, Clerc R, Brousseau E, Montemagno C, Ahmadi M, Bacot S, Soubies A, Perret P, Riou LM, Devoogdt N, Lahoutte T, Barone-Rochette G, Fagret D, Ghezzi C, Sulpice T, Broisat A.
    J Nucl Med; 2017 Jul; 58(7):1088-1093. PubMed ID: 28280218
    [Abstract] [Full Text] [Related]

  • 9. Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice.
    Kuhlencordt PJ, Padmapriya P, Rützel S, Schödel J, Hu K, Schäfer A, Huang PL, Ertl G, Bauersachs J.
    Atherosclerosis; 2009 Jan; 202(1):48-57. PubMed ID: 18479686
    [Abstract] [Full Text] [Related]

  • 10. Dietary cholesterol, cholesterol absorption, postprandial lipemia and atherosclerosis.
    Huff MW.
    Can J Clin Pharmacol; 2003 Jan; 10 Suppl A():26A-32A. PubMed ID: 14571303
    [Abstract] [Full Text] [Related]

  • 11. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia.
    Sandoval JC, Nakagawa-Toyama Y, Masuda D, Tochino Y, Nakaoka H, Kawase R, Yuasa-Kawase M, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Ohama T, Matsuyama A, Nishida M, Ishigami M, Komuro I, Yamashita S.
    J Atheroscler Thromb; 2010 Sep 30; 17(9):914-24. PubMed ID: 20543519
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action.
    Moghadasian MH, McManus BM, Godin DV, Rodrigues B, Frohlich JJ.
    Circulation; 1999 Apr 06; 99(13):1733-9. PubMed ID: 10190884
    [Abstract] [Full Text] [Related]

  • 14. Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet.
    Stepankova R, Tonar Z, Bartova J, Nedorost L, Rossman P, Poledne R, Schwarzer M, Tlaskalova-Hogenova H.
    J Atheroscler Thromb; 2010 Aug 31; 17(8):796-804. PubMed ID: 20379054
    [Abstract] [Full Text] [Related]

  • 15. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
    Zheng S, Hoos L, Cook J, Tetzloff G, Davis H, van Heek M, Hwa JJ.
    Eur J Pharmacol; 2008 Apr 14; 584(1):118-24. PubMed ID: 18329014
    [Abstract] [Full Text] [Related]

  • 16. Effects of ezetimibe on atherosclerosis in preclinical models.
    Davis HR, Lowe RS, Neff DR.
    Atherosclerosis; 2011 Apr 14; 215(2):266-78. PubMed ID: 21397230
    [Abstract] [Full Text] [Related]

  • 17. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T.
    Clin Ther; 2007 Nov 14; 29(11):2419-32. PubMed ID: 18158082
    [Abstract] [Full Text] [Related]

  • 18. Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice.
    Koulis C, Chen YC, Hausding C, Ahrens I, Kyaw TS, Tay C, Allen T, Jandeleit-Dahm K, Sweet MJ, Akira S, Bobik A, Peter K, Agrotis A.
    Arterioscler Thromb Vasc Biol; 2014 Mar 14; 34(3):516-25. PubMed ID: 24436372
    [Abstract] [Full Text] [Related]

  • 19. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461.
    Salisbury BG, Davis HR, Burrier RE, Burnett DA, Bowkow G, Caplen MA, Clemmons AL, Compton DS, Hoos LM, McGregor DG.
    Atherosclerosis; 1995 May 14; 115(1):45-63. PubMed ID: 7669087
    [Abstract] [Full Text] [Related]

  • 20. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
    Muraoka T, Aoki K, Iwasaki T, Shinoda K, Nakamura A, Aburatani H, Mori S, Tokuyama K, Kubota N, Kadowaki T, Terauchi Y.
    Metabolism; 2011 May 14; 60(5):617-28. PubMed ID: 20673929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.